BMN 673

Use

BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. BMN 673 demonstrates single-agent cytotoxicityin BRCA-1 mutant (MX-1, IC50 = 0.3 nM) and BRCA-2 mutant cells (Capan-1, IC50 = 5 nM). In contrast, in MRC-5 normal human fibroblastand other tumor cell lines with wild-type BRCA-1 and BRCA-2 genes, IC50 of BMN 673 ranges between 90 nM and 1.9 μM. In cultured human cancer cells, BMN 673 also significantly enhances the cytotoxic efficacy of both Temozolomide and SN-38. Off-target molecular screening did not identify significant non-specific activity for this class of PARP inhibitors.

BMN 673 manufacturers

• Talazoparib
• 
• $35.00
• 2026-07-27
• CAS:1207456-01-6
• Purity: 99.92%
• Supply Ability: 10g

• BMN673/Talazoparib
• 
• 2024-11-26
• CAS:1207456-01-6
• Min. Order: 1kg
• Purity: 99%, Single impurity＜0.1
• Supply Ability: 1 ton

• Talazoparib
• 
• $10.00
• 2021-07-13
• CAS:1207456-01-6
• Min. Order: 1KG
• Purity: 99%+ HPLC